Date: 2014-10-08
Type of information: Fundraising
Company: Mimetas (The Netherlands)
Investors: Zeeuws Investerings Fonds (ZIF) (The Netherlands), Participatiemaatschapij Oost Nederland (PPM Oost) (The Netherlands), national and regional partners
Amount: $ 5.2 million (€4.1 million)
Funding type: fundraising
Planned used: Mimetas will use the funds to scale up the production of OrganoPlates™ and strengthen its activities in predictive preclinical model development. Currently, Mimetas has a range of disease-, toxicology- and ADME models in the pipeline, in various stages of development and validation. Mimetas’ OrganoPlates™ are microfluidics?based culture plates that enable culturing and screening of a range of organ and tissue models. All OrganoPlates™ are based on industry-standard 384-well microplates. The selected materials used assure a free optical path and full compatibility with all microscopy and readout equipment, including confocal microscopy and luminescent readers. The plates are compatible with industrial screening robots and high-content imaging equipment. Mimetas offers both standardized OrganoPlates™ as well as custom designed plates.
Others: * On October 8, 2014, Mimetis announced that it has raised $ 5.2 million to fund its expansion as a global leader in organ-on-a-chip technology. Venture capital investors Zeeuws Investerings Fonds (ZIF) and Participatiemaatschapij Oost Nederland (PPM Oost) have joined forces with national and regional partners to fund development and sales of Mimetas’ unique 3D disease- and tissue modelling technologies. The company has recently announced a $ 1.6 million kidney-on-a-chip project with Roche, Pfizer and GSK.
Therapeutic area: Technology - Services
